In a move that may signal a significant shift in US drug policy, the Department of Health and Human Services (HHS) recommended a substantial adjustment in the official legal treatment of cannabis. On August 29, 2023, following nearly an entire year of analytical review of the current standing of cannabis as a Schedule 1 substance, the HHS put forth a recommendation to the Drug Enforcement Administration (DEA) proposing that cannabis be switched from Schedule I to Schedule III.
The DEA still retains the final authority on implementation of said change. However, this recommendation from HHS is the strongest indication yet that a transformation of the decades-long federal classification of cannabis might be on the horizon. This recommendation came after extensive scientific research and a rigorous process of legal evaluation that reveals a growing trend toward recognition of potential medical and social uses for cannabis that could outweigh its risks.
Under the existing Controlled Substances Act, a Schedule I status is reserved for substances judged to have a high potential for abuse and no currently accepted medical use. When moved to Schedule III, cannabis would be recognized as having a potential for abuse less than that of Schedule I or II substances and as having accepted medical use. This would greatly facilitate further research and development of cannabis for medical purposes, possibly leading to the wider availability of medications based on cannabis.
This proposed change by HHS is significant since it might also impact the world of corporate policy, shifting attitudes, and possibly even legislation regarding employer drug testing and the workplace use of cannabis. As we watch the legal landscape shift under these proposed changes, corporations and law firms across the globe would need to adapt to this new landscape.
For the detailed information regarding this major shift, visit here.